Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenapanor for Reducing Hyperoxaluria and Kidney Stone Risk
NCT06481150Phase 4Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hyperoxaluria comparing Tenapanor with Placebo (2 arms). Primary endpoint: Total Urinary Oxalate Excretion at day 5. Started Jul 2024; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperoxaluria
Beyond the preview
Go deeper on NCT06481150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481150.